To further elucidate the role of ALKBH5 in modulating GVAX/anti-PD-1 treatment, they analysed tumor infiltrating lymphocytes (TILs) by FACS and found that among total CD45+CD4+CD8+ gated populations, ALKBH5−/− mice have elevated granzyme-B (GZMB)+CD8+, GZMB+CD4+ T-cell, NK-cell (CD56+) and dendritic cell (DCs: CD45+Ly6C-MHC-II+CD24hiF4/80lo) numbers, but more importantly, T-reg (CD4+Foxp3+) and polymorphonuclear myeloid derived suppressor cell (PMN-MDSCs: CD45+CD11b+Ly6G+Ly6CloF4/80−MHC-II−) populations were drastically reduced as compared to the control mice. This evidence concerns the gene PTPRC and neoplasm.